<p>2025 年 11 月 28 日- 下午 01:05</p>
<p><strong>收购推进了 INVO 的全国扩张战略，增强了其临床能力，并扩大了中西部地区创新生育护理的可及性</strong></p>
<p>佛罗里达州萨拉索塔和印第安纳波利斯，2025 年 11 月 28 日（GLOBE NEWSWIRE）-- INVO Fertility, Inc.（纳斯达克：IVF）（“INVO” 或 “公司”）是一家专注于生育诊所及相关业务和技术的医疗保健生育公司，今天宣布其收购 Family Beginnings, P.C.的意图，该诊所是一家受人尊敬的生育诊所，为印第安纳州及更广泛的中西部地区的患者提供服务。此次计划收购标志着 INVO 在 2023 年收购威斯康星生育研究所后的第二次收购，反映了公司多方位的战略举措，旨在建立一个能够覆盖服务不足市场并满足日益增长的患者需求的全国生育中心网络。</p>
<p>“Family Beginnings 长期以来因其卓越的护理标准而受到认可，我们非常高兴能欢迎 James Donahue 博士及其优秀团队加入 INVO 大家庭，” INVO 首席执行官 Steve Shum 表示。“从我们最初的对话中，很明显我们在以患者为中心的同情治疗理念上有着共同的哲学。同样令人兴奋的是，Donahue 博士是我们创新的 INVOcell 技术的早期采用者，并且仍然是其强有力的倡导者。我们的阴道内培养（“IVC”）解决方案已很好地融入他的实践中，并且是提供给患者的几种治疗选择之一。与 Donahue 博士及 Family Beginnings 团队的合作是我们战略增长努力的重要一步，我们期待在中西部地区扩大我们的影响力，支持他们的持续成功。”</p>
<p>Family Beginnings 成立于 1990 年代末，已为印第安纳州及周边州的数千名患者提供服务。该诊所以个性化护理模式和强大的成功率而闻名，提供全面的生殖服务，包括以下内容：</p>
<ul>
<li>体外受精（IVF）；</li>
<li>INVOcell（IVC）；</li>
<li>子宫内人工授精（IUI）；</li>
<li>第三方生育服务；</li>
<li>生育保存；</li>
<li>高级诊断测试；以及</li>
<li>全面的患者教育和支持项目</li>
</ul>
<p>“我们很高兴与 INVO Fertility 携手合作，” Family Beginnings 的创始人 James Donahue 博士（HCLD）表示。“我们的团队对帮助个人和家庭实现他们的父母梦想有着深厚的承诺。通过与 INVO 的合作，我们将能够扩大我们的服务范围，引入新的创新治疗选择，并确保更多患者受益于我们一直提供的高水平护理。这次合作标志着我们诊所和患者激动人心的新篇章的开始。”</p>
<p>通过此次收购，INVO 计划增强 Family Beginnings 诊所的能力：</p>
<ul>
<li>引入扩展的治疗选项；</li>
<li>投资于诊所基础设施和技术，提高工作流程效率；</li>
<li>整合数字患者参与工具，以实现更流畅的沟通和护理协调；以及</li>
<li>利用 INVO 的全国网络，为患者提供更广泛的资源、支持项目和临床专业知识。</li>
</ul>
<p>“这次收购与我们使命的自然契合，即使生育护理更具可及性和以患者为中心，” Shum 总结道。“像这样的战略收购是我们增长计划的核心组成部分，因为它们使我们能够加速扩张，同时整合经过验证的团队和临床基础设施。我们在一个多月前与 Donahue 博士签署了条款清单，目前正在完成最终协议，并预计将在近期内完成交易。”</p>
<p>此次收购仍需 INVO 完成常规尽职调查，并与 Family Beginnings 进行谈判并签署最终购买协议。最终协议还预计将包括常规契约、成交条件、任何所需的监管批准、赔偿条款和终止权利。不能保证 INVO 将签署最终协议或完成收购。</p>
<p><strong>关于 INVO Fertility</strong></p>
<p>我们是一家医疗服务生育公司，致力于扩大对需要辅助生殖技术（“ART”）护理的患者的可及性。我们的主要商业战略集中在建立、收购和运营生育诊所，包括主要提供由我们的 INVOcell®医疗设备（“INVOcell”）支持的阴道内培养（“IVC”）程序的 “INVO 中心” 和美国本土的盈利体外受精（“IVF”）诊所。我们在美国有两个运营中的 INVO 中心和一个 IVF 诊所。我们还继续参与向第三方拥有和运营的生育诊所销售和分销 INVOcell。INVOcell 是一种专有的革命性医疗设备，是首个允许受精和早期胚胎发育在女性体内进行的设备。IVC 程序为患者提供了比其他 ART 治疗更紧密、亲密和经济实惠的体验。我们相信 IVC 程序可以以传统 IVF 成本的一小部分提供可比的结果，并且比子宫内人工授精更有效。有关更多信息，请访问 invofertility.com。</p>
<p><strong>安全港声明</strong></p>
<p>本公告包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的前瞻性声明。公司引用 1995 年《私人证券诉讼改革法》的保护。所有关于我们预期未来财务状况、经营成果、现金流、融资计划、商业战略、产品和服务、竞争地位、增长机会、管理层未来运营计划和目标的声明，以及包含 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“可以”、“应该”、“将” 等类似表达的声明均为前瞻性声明。这些前瞻性声明包括但不限于关于潜在收购 Family Beginnings 的声明、任何此类潜在收购的条款和条件、是否会按照非约束性条款清单中规定的条款进行收购（如果有的话），以及收购对 INVO 当前和未来产品供应、业务及财务结果和状况的影响。所有前瞻性声明均涉及风险、不确定性和偶发事件，其中许多超出我们的控制，这可能导致实际结果、表现或成就与预期结果、表现或成就有重大差异，包括但不限于 INVO 和 Family Beginnings 无法就 Family Beginnings 业务的非约束性条款清单中规定的条款谈判并达成最终购买协议的风险，尽管执行了最终购买协议，INVO 完成此类收购的能力所面临的监管及其他风险，以及如果收购发生，整合 Family Beginnings 业务的其他风险和不确定性，以及 INVO 是否能从收购中实现其期望的业务、运营和财务结果。导致实际结果与前瞻性声明中所述结果有重大差异的因素包括我们在 <strong>www.sec.gov</strong> 的文件中列出的因素。我们没有义务（并明确拒绝任何此类义务）更新或更改我们的前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p><strong>INVO Fertility, Inc.</strong></p>
<p><strong>Steve Shum, CEO</strong></p>
<p>978-878-9505</p>
<p>sshum@invofertility.com</p>
<p><strong>投资者联系</strong></p>
<p><strong>Lytham Partners, LLC</strong></p>
<p><strong>Robert Blum</strong></p>
<p>602-889-9700</p>
<p>INVO@lythampartners.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png"/></p>

<p>INVO Fertility 宣布其计划收购位于印第安纳州的生育诊所 Family Beginnings，作为其全国扩张战略的一部分。此次收购旨在增强 INVO 的临床能力，并扩大中西部地区的生育护理服务。该收购需经过常规尽职调查和最终协议。INVO 计划在 Family Beginnings 引入更多的治疗选择，并整合数字工具。这一举措与 INVO 的使命相一致，即使生育护理更加可及和以患者为中心</p>

<p>11/28/2025 - 01:05 PM</p>
<div class="lb-trans"><p>2025 年 11 月 28 日- 下午 01:05</p>
</div><p><strong>Acquisition advances INVO’s national expansion strategy, enhances its clinical capabilities, and broadens access to innovative fertility care across the Midwest</strong></p>
<div class="lb-trans"><p><strong>收购推进了 INVO 的全国扩张战略，增强了其临床能力，并扩大了中西部地区创新生育护理的可及性</strong></p>
</div><p>SARASOTA, Fla. and INDIANAPOLIS, Nov. 28, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced its intent to acquire Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The planned acquisition marks INVO’s second acquisition after its purchase of Wisconsin Fertility Institute in 2023 and reflects the Company’s multi-pronged strategic initiative to build a nationwide network of fertility centers capable of reaching underserved markets and meeting rising patient demand.</p>
<div class="lb-trans"><p>佛罗里达州萨拉索塔和印第安纳波利斯，2025 年 11 月 28 日（GLOBE NEWSWIRE）-- INVO Fertility, Inc.（纳斯达克：IVF）（“INVO” 或 “公司”）是一家专注于生育诊所及相关业务和技术的医疗保健生育公司，今天宣布其收购 Family Beginnings, P.C.的意图，该诊所是一家受人尊敬的生育诊所，为印第安纳州及更广泛的中西部地区的患者提供服务。此次计划收购标志着 INVO 在 2023 年收购威斯康星生育研究所后的第二次收购，反映了公司多方位的战略举措，旨在建立一个能够覆盖服务不足市场并满足日益增长的患者需求的全国生育中心网络。</p>
</div><p>“Family Beginnings has long been recognized for its exceptional standards of care, and we are thrilled to welcome Dr. James Donahue and his talented team into the INVO family,” said Steve Shum, CEO of INVO. “From our earliest conversations, it was clear that we share a common philosophy centered on compassionate, patient-first treatment. Equally as exciting, Dr. Donahue was an early adopter and remains a strong advocate of our innovative INVOcell technology. Our intravaginal culture (“IVC”) solution is well integrated into his practice and is one of the several treatment options offered to patients. Teaming up with Dr. Donahue and the Family Beginnings team is an important step in pursuit of our strategic growth efforts, and we look forward to supporting their continued success as we expand our presence across the Midwest.”</p>
<div class="lb-trans"><p>“Family Beginnings 长期以来因其卓越的护理标准而受到认可，我们非常高兴能欢迎 James Donahue 博士及其优秀团队加入 INVO 大家庭，” INVO 首席执行官 Steve Shum 表示。“从我们最初的对话中，很明显我们在以患者为中心的同情治疗理念上有着共同的哲学。同样令人兴奋的是，Donahue 博士是我们创新的 INVOcell 技术的早期采用者，并且仍然是其强有力的倡导者。我们的阴道内培养（“IVC”）解决方案已很好地融入他的实践中，并且是提供给患者的几种治疗选择之一。与 Donahue 博士及 Family Beginnings 团队的合作是我们战略增长努力的重要一步，我们期待在中西部地区扩大我们的影响力，支持他们的持续成功。”</p>
</div><p>Founded in the late 1990s, Family Beginnings has served thousands of patients across Indiana and surrounding states. Known for its personalized care model and strong success rates, the clinic offers a full suite of reproductive services, including the following:</p>
<div class="lb-trans"><p>Family Beginnings 成立于 1990 年代末，已为印第安纳州及周边州的数千名患者提供服务。该诊所以个性化护理模式和强大的成功率而闻名，提供全面的生殖服务，包括以下内容：</p>
</div><ul>
<li>In vitro fertilization (IVF);</li>
<li>INVOcell (IVC);</li>
<li>Intrauterine insemination (IUI);</li>
<li>Third-party reproduction services;</li>
<li>Fertility preservation;</li>
<li>Advanced diagnostic testing; and</li>
<li>Comprehensive patient education and support programs</li>
</ul>
<div class="lb-trans"><ul>
<li>体外受精（IVF）；</li>
<li>INVOcell（IVC）；</li>
<li>子宫内人工授精（IUI）；</li>
<li>第三方生育服务；</li>
<li>生育保存；</li>
<li>高级诊断测试；以及</li>
<li>全面的患者教育和支持项目</li>
</ul>
</div><p>“We are excited to join forces with INVO Fertility,” said James Donahue M.D., HCLD and founder of Family Beginnings. “Our teams share a deep commitment to helping individuals and families achieve their dreams of parenthood. By partnering with INVO, we will be able to broaden our offerings, introduce new and innovative treatment options, and ensure that even more patients benefit from the high level of care we’ve always provided. This collaboration marks the beginning of an exciting new chapter for our clinic and our patients.”</p>
<div class="lb-trans"><p>“我们很高兴与 INVO Fertility 携手合作，” Family Beginnings 的创始人 James Donahue 博士（HCLD）表示。“我们的团队对帮助个人和家庭实现他们的父母梦想有着深厚的承诺。通过与 INVO 的合作，我们将能够扩大我们的服务范围，引入新的创新治疗选择，并确保更多患者受益于我们一直提供的高水平护理。这次合作标志着我们诊所和患者激动人心的新篇章的开始。”</p>
</div><p>With this acquisition, INVO plans to enhance the Family Beginnings clinic by:</p>
<div class="lb-trans"><p>通过此次收购，INVO 计划增强 Family Beginnings 诊所的能力：</p>
</div><ul>
<li>Introducing expanded treatment options;</li>
<li>Investing in clinic infrastructure and technology, improving workflow efficiencies;</li>
<li>Integrating digital patient engagement tools for streamlined communication and care coordination; and</li>
<li>Leveraging INVO’s national network to provide patients with broader access to resources, support programs, and clinical expertise.</li>
</ul>
<div class="lb-trans"><ul>
<li>引入扩展的治疗选项；</li>
<li>投资于诊所基础设施和技术，提高工作流程效率；</li>
<li>整合数字患者参与工具，以实现更流畅的沟通和护理协调；以及</li>
<li>利用 INVO 的全国网络，为患者提供更广泛的资源、支持项目和临床专业知识。</li>
</ul>
</div><p>“This acquisition is a natural fit with our mission to make fertility care more accessible and patient-centered,” concluded Shum. “Strategic acquisitions like this are a core component of our growth plan, as they allow us to accelerate expansion while integrating proven teams and clinical infrastructure. Having executed a term sheet with Dr. Donahue over a month ago, we are well along in completing final agreements and expect to close the transaction in the near-term.”</p>
<div class="lb-trans"><p>“这次收购与我们使命的自然契合，即使生育护理更具可及性和以患者为中心，” Shum 总结道。“像这样的战略收购是我们增长计划的核心组成部分，因为它们使我们能够加速扩张，同时整合经过验证的团队和临床基础设施。我们在一个多月前与 Donahue 博士签署了条款清单，目前正在完成最终协议，并预计将在近期内完成交易。”</p>
</div><p>The acquisition remains subject to completion of customary due diligence by INVO and the negotiation and entry into definitive purchase agreements between INVO and Family Beginnings. The definitive agreements are also expected to include customary covenants, closing conditions, any required regulatory approvals, indemnification provisions and termination rights. There can be no assurances that INVO will enter into a definitive agreement or complete the acquisition.</p>
<div class="lb-trans"><p>此次收购仍需 INVO 完成常规尽职调查，并与 Family Beginnings 进行谈判并签署最终购买协议。最终协议还预计将包括常规契约、成交条件、任何所需的监管批准、赔偿条款和终止权利。不能保证 INVO 将签署最终协议或完成收购。</p>
</div><p><strong>About INVO Fertility</strong></p>
<div class="lb-trans"><p><strong>关于 INVO Fertility</strong></p>
</div><p>We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place <em>in vivo</em> within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.</p>
<div class="lb-trans"><p>我们是一家医疗服务生育公司，致力于扩大对需要辅助生殖技术（“ART”）护理的患者的可及性。我们的主要商业战略集中在建立、收购和运营生育诊所，包括主要提供由我们的 INVOcell®医疗设备（“INVOcell”）支持的阴道内培养（“IVC”）程序的 “INVO 中心” 和美国本土的盈利体外受精（“IVF”）诊所。我们在美国有两个运营中的 INVO 中心和一个 IVF 诊所。我们还继续参与向第三方拥有和运营的生育诊所销售和分销 INVOcell。INVOcell 是一种专有的革命性医疗设备，是首个允许受精和早期胚胎发育在女性体内进行的设备。IVC 程序为患者提供了比其他 ART 治疗更紧密、亲密和经济实惠的体验。我们相信 IVC 程序可以以传统 IVF 成本的一小部分提供可比的结果，并且比子宫内人工授精更有效。有关更多信息，请访问 invofertility.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as &#34;anticipate,&#34; &#34;if,&#34; &#34;believe,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;will,&#34; and other similar expressions are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential acquisition of Family Beginnings, the terms and conditions of any such potential acquisition, whether such acquisition will occur on the terms set forth in the non-binding term sheet, if at all, and the impact of the acquisition on INVO’s current and future product offerings, business, and financial results and condition. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements , including but not limited to the risks that INVO and Family Beginnings will not be able to negotiate and enter into a definitive purchase agreement for the Family Beginnings business on terms set forth in the non-binding term sheet or at all, regulatory and other risks associated with INVO’s ability to complete such an acquisition even if a definitive purchase agreement is executed, and, if it occurs, other risks and uncertainties associated with the integration of the Family Beginnings business and whether INVO will achieve its desired or expected business, operational, and financial outcomes from the acquisition. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at <strong>www.sec.gov</strong>. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本公告包含根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的前瞻性声明。公司引用 1995 年《私人证券诉讼改革法》的保护。所有关于我们预期未来财务状况、经营成果、现金流、融资计划、商业战略、产品和服务、竞争地位、增长机会、管理层未来运营计划和目标的声明，以及包含 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“可以”、“应该”、“将” 等类似表达的声明均为前瞻性声明。这些前瞻性声明包括但不限于关于潜在收购 Family Beginnings 的声明、任何此类潜在收购的条款和条件、是否会按照非约束性条款清单中规定的条款进行收购（如果有的话），以及收购对 INVO 当前和未来产品供应、业务及财务结果和状况的影响。所有前瞻性声明均涉及风险、不确定性和偶发事件，其中许多超出我们的控制，这可能导致实际结果、表现或成就与预期结果、表现或成就有重大差异，包括但不限于 INVO 和 Family Beginnings 无法就 Family Beginnings 业务的非约束性条款清单中规定的条款谈判并达成最终购买协议的风险，尽管执行了最终购买协议，INVO 完成此类收购的能力所面临的监管及其他风险，以及如果收购发生，整合 Family Beginnings 业务的其他风险和不确定性，以及 INVO 是否能从收购中实现其期望的业务、运营和财务结果。导致实际结果与前瞻性声明中所述结果有重大差异的因素包括我们在 <strong>www.sec.gov</strong> 的文件中列出的因素。我们没有义务（并明确拒绝任何此类义务）更新或更改我们的前瞻性声明，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p><strong>INVO Fertility, Inc.</strong></p>
<div class="lb-trans"><p><strong>INVO Fertility, Inc.</strong></p>
</div><p><strong>Steve Shum, CEO</strong></p>
<div class="lb-trans"><p><strong>Steve Shum, CEO</strong></p>
</div><p>978-878-9505</p>
<div class="lb-trans"><p>978-878-9505</p>
</div><p>sshum@invofertility.com</p>
<div class="lb-trans"><p>sshum@invofertility.com</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p><strong>Lytham Partners, LLC</strong></p>
<div class="lb-trans"><p><strong>Lytham Partners, LLC</strong></p>
</div><p><strong>Robert Blum</strong></p>
<div class="lb-trans"><p><strong>Robert Blum</strong></p>
</div><p>602-889-9700</p>
<div class="lb-trans"><p>602-889-9700</p>
</div><p>INVO@lythampartners.com</p>
<div class="lb-trans"><p>INVO@lythampartners.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU16YzVNaU0zTWprMk5EVTBJekl5T1RBNU9Eaz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5Mzc5MiM3Mjk2NDU0IzIyOTA5ODk="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YWIzOGUzOWQtNmVlOC00OTI4LWFlNGMtOTMyNjcyZDlkZDYxLTEzMDI1MzktMjAyNS0xMS0yOC1lbg==/tiny/INVO-Fertility-Inc-.png"/></p>

INVO Fertility 宣布其计划收购印第安纳州的生育诊所 “Family Beginnings” | IVF 股票新闻